Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:38:09.521Z.
Consensus retrieved: 2026-10-06T14:05:01.105Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:38:09.521Z.
Quote observation: 2026-10-06T16:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2ce25f957fe83095360266a8eba44a0c9f304ca71e6017df3a9cc6b1c586d311
Forward PE Ratio (N/A) = Dated Quote Price ($9.36) / Consensus Forward EPS ($-4.94)
FORWARD PE RATIO
N/A
MapLight Therapeutics, Inc.
Market Cap
$396.99M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $396.99M | N/A |
| REGENXBIO Inc. (RGNX)vs › | $390.83M | N/A |
| Carlsmed, Inc. (CARL)vs › | $404.72M | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $387.04M | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $383.62M | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $410.38M | N/A |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $411.29M | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $411.45M | N/A |
| Neurogene Inc. (NGNE)vs › | $411.65M | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $379.66M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $9.36, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.94 | $-5.36 – $-4.48 | 8 | n/m |
| 2027-12-31 | $-3.86 | $-4.38 – $-3.15 | 9 | n/m |
| 2028-12-31 | $-3.97 | $-5.07 – $-3.27 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
